SCHEMBL6207049

SCHEMBL6207049

Cc1ccc(CCCCCCO)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.57
ALOX15 P16050 1/20 0.57
CA2 P00918 2/20 0.53
CYP4A11 Q02928 2/20 0.52
CYP4F2 P78329 1/20 0.52
CYP1A2 P05177 1/20 0.48
CYP2A6 P11509 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
HRH1 P35367 1/20 0.47
ESR1 P03372 2/20 0.47
ADRA2A P08913 2/20 0.47
ADORA3 P0DMS8 2/20 0.47
TACR2 P21452 2/20 0.47
SLC6A2 P23975 2/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A3 Q01959 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
SHBG P04278 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12827576 1.00 IGF1R (0.57) IGF1RALOX15CA2CYP4A11CYP4F2
SCHEMBL9422698 1.00 IGF1R (0.57) IGF1RALOX15CA2CYP4A11CYP4F2
SCHEMBL93545 1.00 IGF1R (0.57) IGF1RALOX15CA2CYP4A11CYP4F2
P-Xylene SCHEMBL6429103 1.00 IGF1R (0.57) IGF1RALOX15CA2CYP4A11CYP4F2
SCHEMBL11286656 1.00 IGF1R (0.57) IGF1RALOX15CA2CYP4A11CYP4F2
Methyl Alcohol SCHEMBL9951500 0.98 IGF1R (0.55) IGF1RALOX15CA2CYP4A11CYP4F2
SCHEMBL285785 0.98 IGF1R (0.59) IGF1RALOX15CA2CYP4A11CYP4F2
SCHEMBL80441 0.91 IGF1R (0.55) IGF1RALOX15CA2CYP4A11CYP4F2
Toluene SCHEMBL7575476 0.90 IGF1R (0.52) IGF1RALOX15CA2CYP4A11CYP4F2
SCHEMBL18214664 0.89 IGF1R (0.47) IGF1RALOX15CA2CYP4A11CYP4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1564200-A1 Ketone compounds and compositions for cholesterol management and related uses Esperion Therapeutics Inc. (US) 2005-08-17 EP disclosed
EP-0341249-B1 DEVELOPING SYSTEM AND A METHOD OF USING THE DEVELOPING SYSTEM FOR DETECTION OF CARBOXYLIC ACIDS LITMUS CONCEPTS INC (US) 1994-07-13 EP disclosed
US-5194666-A Intermediates for chemiluminescent agents, chlorination, esterification AMERICAN CYANAMID COMPANY (US) 1993-03-16 US disclosed
EP-0341249-A4 DEVELOPING SYSTEM AND A METHOD OF USING THE DEVELOPING SYSTEM FOR DETECTION OF CARBOXYLIC ACIDS LITMUS CONCEPTS INC (US) 1990-12-05 EP disclosed
EP-0341249-A1 DEVELOPING SYSTEM AND A METHOD OF USING THE DEVELOPING SYSTEM FOR DETECTION OF CARBOXYLIC ACIDS. LITMUS CONCEPTS INC (US) 1989-11-15 EP disclosed
US-4777143-A FORMING METAL COMPLEX WHICH CATALYZES OXIDATION OF CHROMOGEN LITMUS CONCEPTS INC. (US) 1988-10-11 US disclosed
WO-1988004427-A1 DEVELOPING SYSTEM AND A METHOD OF USING THE DEVELOPING SYSTEM FOR DETECTION OF CARBOXYLIC ACIDS LITMUS CONCEPTS, INC. (US) 1988-06-16 WO disclosed
US-4308395-A Processes for preparing 3,5,6-trichlorosalicylic acid and esters thereof AMERICAN CYANAMID COMPANY (US) 1981-12-29 US disclosed